Skip to content

Operative Versus Non-operative Treatment for Mild to Moderate Hallux Valgus Deformity

Randomised Controlled Trial; Is Operative Treatment of Mild to Moderate Hallux Valgus Deformity Superior to Conservative Treatment?

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06114043
Enrollment
120
Registered
2023-11-02
Start date
2025-06-01
Completion date
2030-03-31
Last updated
2025-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hallux Valgus Deformity

Brief summary

The goal of this randomized controlled trial is to investigate operative treatment versus conservative treatment in participants suffering from mild to moderate hallux valgus deformity. The main question it aims to answer are; Is surgery superior to conservative treatment? The participants will be randomized in to two groups, operative and conservative group. Investigators will compare the groups measuring the clinical results using the patient-reported outcome measure (PROM) Manchester-Oxford Foot Questionnaire (MOxFQ), Visual analog scale (VAS), likert scale 0-5. Participants will be observed for a period og two years.

Detailed description

Randomized controlled trial (RCT) investigating the patient reported outcome after operative or conservative treatment in mild to moderate hallux valgus deformity. In this RCT study participants will be divided into operative group, non-operative group where the treatment will be orthopedic aids/wide shoes. The participants will be evaluated 6 months, 1 year and 2 years after starting the treatment. The clinical results will be evaluated using patient reported outcome measures (PROMs). Primary aim: Investigating the clinical result by PROM (Manchester Oxford Foot Questionnaire) Secondary aim: Investigating the radiological results according to newer and traditional parameters. Operative group -correction achieved, residual rate. Conservative group -progression of deformity. Statistical power calculations have been made within the research group. Calculations are based on the main outcome MOxFQ, with the power of 80 and confidence interval 95%. The investigators concluded that a sample size of 49 participants will be needed to perform a regression analysis. To account for loss to follow-up (estimated 20%),120 participants (60 per group) will be recruited.

Interventions

OTHERConservative treatment with orthopedic aid/wide shoe for participants with mild to moderate hallux valgus

60 participants will receive conservative treatment with orthopedic aid/wide shoe. Participants will be followed for 2 years.

OTHEROperation for mild to moderate hallux valgus

60 participants will receive the traditional operative treatment for the deformity. Participants will be followed for 2 years.

Sponsors

Ostfold Hospital Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Intervention model description

Randomised controlled trial investigating patients with painful mild to moderate hallux valgus deformity

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Painful Hallux Valgus deformity * Hallux Valgus Angle \<35 degrees * Intermetatarsal angle \<15 degrees * 18-80 years

Exclusion criteria

* Advanced osteoarthritis in first metatarsophalangeal joint * Rheumatic diseases * Pregnancy * Drug abuse * Severe psychological disorder * Lack of compliance * Language barrier

Design outcomes

Primary

MeasureTime frameDescription
Clinical results MOxFQ2 yearsManchester oxford foot questionnaire (MOxFQ) (Raw scores can be converted to a 0-100 metric where 100=most severe)

Secondary

MeasureTime frameDescription
Clinical result VAS2 yearsVisual analogue scale (VAS) 0-10 (0=best to 10=worst)
Clinical result SF-362 yearsShort Form Health Survey (SF-36) (0=worst to 100=best)
Clinical result Likert scale2 yearsLikert scale 0-5 (0=worst to 5=best)

Countries

Norway

Contacts

Primary ContactMarius Molund
marius.molund@so-hf.no90093988
Backup ContactMikaela E Hamre
mikaela.engaras.hamre@so-hf.no+4741273586

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026